Positron emission tomography imaging of tau pathology in progressive supranuclear palsy

Sarah Coakeley, Sang Soo Cho, Yuko Koshimori, Pablo Rusjan, Madeleine Harris, Christine Ghadery, Jinhee Kim, Anthony E. Lang, Alan Wilson, Sylvain Houle, Antonio P. Strafella

Research output: Contribution to journalArticle

Abstract

Progressive supranuclear palsy is a rare form of atypical Parkinsonism that differs neuropathologically from other parkinsonian disorders. While many parkinsonian disorders such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy are classified as synucleinopathies, progressive supranuclear palsy is coined a tauopathy due to the aggregation of pathological tau in the brain. [18F]AV-1451 (also known as [18F]-T807) is a positron emission tomography radiotracer that binds to paired helical filaments of tau in Alzheimer’s disease. We investigated whether [18F]AV-1451 could be used as biomarker for the diagnosis and disease progression monitoring in progressive supranuclear palsy. Six progressive supranuclear palsy, six Parkinson’s disease, and 10 age-matched healthy controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio from 60 to 90 min post-injection was calculated in each region of interest, using the cerebellar cortex as a reference region. No significant differences in standardized uptake value ratios were detected in our progressive supranuclear palsy group compared to the two control groups. [18F]AV-1451 may bind selectivity to the paired helical filaments in Alzheimer’s disease, which differ from the straight conformation of tau filaments in progressive supranuclear palsy.

Original languageEnglish (US)
Pages (from-to)3150-3160
Number of pages11
JournalJournal of Cerebral Blood Flow and Metabolism
Volume37
Issue number9
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Progressive Supranuclear Palsy
Positron-Emission Tomography
Pathology
Parkinsonian Disorders
Alzheimer Disease
Tauopathies
Multiple System Atrophy
Lewy Body Disease
Cerebellar Cortex
Parkinson Disease
Disease Progression
Biomarkers
Control Groups
Injections
Brain

Keywords

  • Brain imaging
  • movement disorder
  • neuropathology
  • Parkinson’s disease
  • positron emission tomography

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. / Coakeley, Sarah; Cho, Sang Soo; Koshimori, Yuko; Rusjan, Pablo; Harris, Madeleine; Ghadery, Christine; Kim, Jinhee; Lang, Anthony E.; Wilson, Alan; Houle, Sylvain; Strafella, Antonio P.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 37, No. 9, 01.09.2017, p. 3150-3160.

Research output: Contribution to journalArticle

Coakeley, S, Cho, SS, Koshimori, Y, Rusjan, P, Harris, M, Ghadery, C, Kim, J, Lang, AE, Wilson, A, Houle, S & Strafella, AP 2017, 'Positron emission tomography imaging of tau pathology in progressive supranuclear palsy', Journal of Cerebral Blood Flow and Metabolism, vol. 37, no. 9, pp. 3150-3160. https://doi.org/10.1177/0271678X16683695
Coakeley, Sarah ; Cho, Sang Soo ; Koshimori, Yuko ; Rusjan, Pablo ; Harris, Madeleine ; Ghadery, Christine ; Kim, Jinhee ; Lang, Anthony E. ; Wilson, Alan ; Houle, Sylvain ; Strafella, Antonio P. / Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. In: Journal of Cerebral Blood Flow and Metabolism. 2017 ; Vol. 37, No. 9. pp. 3150-3160.
@article{0d38c4232ab54e1c969790a2ace22f9c,
title = "Positron emission tomography imaging of tau pathology in progressive supranuclear palsy",
abstract = "Progressive supranuclear palsy is a rare form of atypical Parkinsonism that differs neuropathologically from other parkinsonian disorders. While many parkinsonian disorders such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy are classified as synucleinopathies, progressive supranuclear palsy is coined a tauopathy due to the aggregation of pathological tau in the brain. [18F]AV-1451 (also known as [18F]-T807) is a positron emission tomography radiotracer that binds to paired helical filaments of tau in Alzheimer’s disease. We investigated whether [18F]AV-1451 could be used as biomarker for the diagnosis and disease progression monitoring in progressive supranuclear palsy. Six progressive supranuclear palsy, six Parkinson’s disease, and 10 age-matched healthy controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio from 60 to 90 min post-injection was calculated in each region of interest, using the cerebellar cortex as a reference region. No significant differences in standardized uptake value ratios were detected in our progressive supranuclear palsy group compared to the two control groups. [18F]AV-1451 may bind selectivity to the paired helical filaments in Alzheimer’s disease, which differ from the straight conformation of tau filaments in progressive supranuclear palsy.",
keywords = "Brain imaging, movement disorder, neuropathology, Parkinson’s disease, positron emission tomography",
author = "Sarah Coakeley and Cho, {Sang Soo} and Yuko Koshimori and Pablo Rusjan and Madeleine Harris and Christine Ghadery and Jinhee Kim and Lang, {Anthony E.} and Alan Wilson and Sylvain Houle and Strafella, {Antonio P.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1177/0271678X16683695",
language = "English (US)",
volume = "37",
pages = "3150--3160",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Positron emission tomography imaging of tau pathology in progressive supranuclear palsy

AU - Coakeley, Sarah

AU - Cho, Sang Soo

AU - Koshimori, Yuko

AU - Rusjan, Pablo

AU - Harris, Madeleine

AU - Ghadery, Christine

AU - Kim, Jinhee

AU - Lang, Anthony E.

AU - Wilson, Alan

AU - Houle, Sylvain

AU - Strafella, Antonio P.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Progressive supranuclear palsy is a rare form of atypical Parkinsonism that differs neuropathologically from other parkinsonian disorders. While many parkinsonian disorders such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy are classified as synucleinopathies, progressive supranuclear palsy is coined a tauopathy due to the aggregation of pathological tau in the brain. [18F]AV-1451 (also known as [18F]-T807) is a positron emission tomography radiotracer that binds to paired helical filaments of tau in Alzheimer’s disease. We investigated whether [18F]AV-1451 could be used as biomarker for the diagnosis and disease progression monitoring in progressive supranuclear palsy. Six progressive supranuclear palsy, six Parkinson’s disease, and 10 age-matched healthy controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio from 60 to 90 min post-injection was calculated in each region of interest, using the cerebellar cortex as a reference region. No significant differences in standardized uptake value ratios were detected in our progressive supranuclear palsy group compared to the two control groups. [18F]AV-1451 may bind selectivity to the paired helical filaments in Alzheimer’s disease, which differ from the straight conformation of tau filaments in progressive supranuclear palsy.

AB - Progressive supranuclear palsy is a rare form of atypical Parkinsonism that differs neuropathologically from other parkinsonian disorders. While many parkinsonian disorders such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy are classified as synucleinopathies, progressive supranuclear palsy is coined a tauopathy due to the aggregation of pathological tau in the brain. [18F]AV-1451 (also known as [18F]-T807) is a positron emission tomography radiotracer that binds to paired helical filaments of tau in Alzheimer’s disease. We investigated whether [18F]AV-1451 could be used as biomarker for the diagnosis and disease progression monitoring in progressive supranuclear palsy. Six progressive supranuclear palsy, six Parkinson’s disease, and 10 age-matched healthy controls were recruited. An anatomical MRI and a 90-min PET scan, using [18F]AV-1451, were acquired from all participants. The standardized uptake value ratio from 60 to 90 min post-injection was calculated in each region of interest, using the cerebellar cortex as a reference region. No significant differences in standardized uptake value ratios were detected in our progressive supranuclear palsy group compared to the two control groups. [18F]AV-1451 may bind selectivity to the paired helical filaments in Alzheimer’s disease, which differ from the straight conformation of tau filaments in progressive supranuclear palsy.

KW - Brain imaging

KW - movement disorder

KW - neuropathology

KW - Parkinson’s disease

KW - positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85028597582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028597582&partnerID=8YFLogxK

U2 - 10.1177/0271678X16683695

DO - 10.1177/0271678X16683695

M3 - Article

C2 - 28155586

AN - SCOPUS:85028597582

VL - 37

SP - 3150

EP - 3160

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 9

ER -